NASDAQ · Biotechnology

NTLA (NTLA) Stock

$10.89 +2.06% NASDAQ: NTLA Healthcare

Valuation

MetricValue
Price$10.89
Market Cap$1.22B
P/E Ratio-3.55
P/B Ratio2.26
P/S Ratio21.54
EPS (TTM)$-3.81
52-Week High$28.25
52-Week Low$7.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-61.55%
ROA-49.05%
ROCE-65.72%
Gross Margin-648.53%
Operating Margin-648.53%
Net Margin-5.97%
Debt/Equity0.13
Current Ratio5.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$33.0M$52.0M$36.0M$58.0M$68.0M
Operating Profit$-268.0M$-458.0M$-515.0M$-534.0M$-441.0M
Net Profit$-268.0M$-474.0M$-481.0M$-519.0M$-413.0M
EPS$-3.78$-6.16$-5.42$-5.25$-3.81
Op Margin-810.4%-879.0%-1420.5%-923.1%-651.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$1.5B$1.3B$1.2B$842.0M
Total Liabilities$254.0M$285.0M$251.0M$319.0M$171.0M
Cash$123.0M$524.0M$227.0M$189.0M$155.0M
Borrowings$74.0M$131.0M$115.0M$210.0M$93.0M

Latest News

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success Simply Wall St. · Jul 9, 2026 NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? Zacks · Jul 9, 2026 Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns Simply Wall St. · Jul 9, 2026 Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears Barchart · Jul 8, 2026 A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics Motley Fool · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-225.0M$-333.0M$-394.0M$-349.0M$-349.0M
Investing Cash Flow$-564.0M$102.0M$-45.0M$120.0M$120.0M
Financing Cash Flow$43.0M$17.0M$11.0M$9.0M$54.0M
Net Cash Flow$-39.0M$410.0M$-295.0M$-38.0M$-38.0M
Free Cash Flow$-238.0M$-392.0M$-408.0M$-355.0M$-355.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-25.54%
Quick Ratio6.10
Interest Coverage—
Return 1Y-22.05%
Return 3Y-73.52%
Return 5Y-90.37%

Ownership

Insiders Held3.88%
Institutions Held76.79%
Institutions Float Held79.89%
Institutional HolderSharesReport Date
ARK Investment Management, LLC14,509,2472026-03-31
Blackrock Inc.12,155,8062026-03-31
State Street Corporation6,922,6762026-03-31
Vanguard Portfolio Management LLC6,223,3252026-03-31
Shaw D.E. & Co., Inc.5,728,1772026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCRXBioCryst Pharmaceuticals, Inc. $9.75 +4.39% -5.40 $2.48B 0.00%
BHVN $14.07 +3.19% -6.11 $2.12B 0.00%
IMNM $23.22 +2.83% -8.13 $2.22B 0.00%
PHVS $32.62 -3.05% -9.75 $2.28B 0.00%
STOK $32.19 +0.81% -10.47 $2.08B 0.00%

About NTLA

NTLA is led by CEO John Leonard, employs 403 people, headquartered in US, publicly traded since 2016.

NTLA stock trades at $10.89 with a market capitalization of $1.22B. The stock is valued at a price-to-earnings (P/E) ratio of -3.55, price-to-book of 2.26, price-to-sales of 21.54. Over the past 52 weeks the stock has ranged between $7.95 and $28.25, and currently trades 61.5% below its 52-week high.

On profitability, NTLA generates a return on equity (ROE) of -61.55%, return on capital employed of -65.72%, an operating margin of -648.53%, a net profit margin of -5.97%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides